Podcasts
Latest Podcast
3 October 2022
Renal
Speaker: Dr Jimmy Teo Boon Wee, Dr Tan Li Ping
SC-MY-02373
What is new in SGLT2 inhibitor and CKD?
Our host speaks with Assoc Prof Jimmy Teo, Senior Consultant
nephrologist from National University Hospital Singapore and Dr Tan Li Ping,
Consultant Nephrologist from Ara Damansara Medical Centre Malaysia, to discuss the
baseline characteristics of EMPA-Kidney trial, the latest study in SGLT2 inhibitor
and CKD.Note: Empagliflozin is not indicated for the treatment of chronic kidney disease.
Video Player is loading.
Current Time 0:00
/
Duration 10:04
Loaded: 0.00%
00:00
Stream Type LIVE
Remaining Time -10:04
1x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
- en (Main), selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
×
Reference:
1.
EMPA-KIDNEY Collaborative Group. Nephrol
Dial Transplant. 2022 Jun 23;37(7):1317-1329.
